Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nosopharm SAS

Natural products approach to antibiotic resistance

This article was originally published in Start Up

Executive Summary

Nosopharm SAS aims to address bacterial multidrug resistance to antibiotics, particularly in hospital-acquired gram-negative infections, using an-house drug discovery platform that exploits the microbial diversity of the bacterial genera Xenorhabdus and Photorhabdus.

Advertisement

Related Content

Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel